Literature DB >> 9870145

Type 1 protein tyrosine kinases in benign and malignant breast lesions.

Z Suo1, E Emilsen, K M Tveit, J M Nesland.   

Abstract

AIMS: To determine their significance, we examined the expression pattern of the four epidermal growth factor receptor (EGFR) family members as well as the phosphotyrosine kinase activity in breast tumour tissues. METHODS AND
RESULTS: Fifty-three malignant breast tumours, four breast cancer cell lines, and 10 benign breast tumours were investigated. Fifty-three per cent (28/53) of the malignant tumours expressed EGFR protein, and the majority of these positive tumours were strongly positive. Eighty per cent (8/10) of the benign tumours also expressed EGFR protein, but all in a lower or moderate level. An association between EGFR expression and increasing malignancy grade was found in the group of infiltrating ductal carcinomas. Of the malignant tumours, 35.8% (19/53) expressed c-erbB-2 protein and 17% (9/53) c-erbB-3 protein, while no expression of c-erbB-2 and c-erbB-3 proteins was found in the benign tumours. Contrary to previous reports, we observed c-erbB-4 receptor protein to be less expressed in the malignant breast tumours. The 'normal' breast epithelial cells adjacent to the malignant tumours and the benign tumours demonstrated intensified membrane staining for c-erbB-4, while a number of the malignant tumours demonstrated a weak cytoplasmic staining or were negative. However, several malignant tumours with strong membrane staining for the c-erbB-4 protein were also found. No simple association between the expression of the four receptors and phosphotyrosine kinase activity was found.
CONCLUSION: Our study has revealed a complex expression pattern of the EGFR family members in breast tumour cells. While the data about EGFR, c-erbB-2, c-erbB-3 and phosphotyrosine are largely in line with what has been reported, we found the c-erbB-4 protein expression to be decreased in the malignant tumours.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870145     DOI: 10.1046/j.1365-2559.1998.00498.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

Review 1.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

2.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09

3.  Pregnancy and breast cancer: a population-based study.

Authors:  W Reed; E Hannisdal; E Skovlund; S Thoresen; P Lilleng; J M Nesland
Journal:  Virchows Arch       Date:  2003-05-20       Impact factor: 4.064

4.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

Authors:  Jorge S Reis-Filho; Fernanda Milanezi; Silvia Carvalho; Pete T Simpson; Dawn Steele; Kay Savage; Maryou B K Lambros; Emilio M Pereira; Jahn M Nesland; Sunil R Lakhani; Fernando C Schmitt
Journal:  Breast Cancer Res       Date:  2005-10-25       Impact factor: 6.466

5.  Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.

Authors:  A A Memon; B S Sorensen; P Melgard; L Fokdal; T Thykjaer; E Nexo
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

6.  Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.

Authors:  Y Ito; T Takeda; M Sakon; M Tsujimoto; S Higashiyama; K Noda; E Miyoshi; M Monden; N Matsuura
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

7.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Authors:  D M Abd El-Rehim; S E Pinder; C E Paish; J A Bell; R S Rampaul; R W Blamey; J F R Robertson; R I Nicholson; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

8.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

Authors:  Andrea Sassen; Justine Rochon; Peter Wild; Arndt Hartmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff
Journal:  Breast Cancer Res       Date:  2008-01-08       Impact factor: 6.466

9.  Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma.

Authors:  Tingting Chen; Lan Zhou; Hua Li; Yuan Tian; Junqin Li; Lihua Dong; Yuhua Zhao; Dapeng Wei
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.